Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese

Journal of the Neurological Sciences

Volumn 166, Issue 1, 1999, Pages 47-52

  Fukazawa, Toshiyuki ^a   Yabe, Ichiro ^b   Kikuchi, Seiji ^b   Sasaki, Hidenao ^b   Hamada, Takeshi ^a   Miyasaka, Kazuo ^b   Tashiro, Kunio ^b  

^a Hokuyukai Neurology Hospital   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Japanese; Multiple sclerosis; Polymorphism; Susceptibility gene; Vitamin D receptor

Indexed keywords

RESTRICTION ENDONUCLEASE; VITAMIN D RECEPTOR;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; DNA POLYMORPHISM; FEMALE; GENOTYPE; HLA SYSTEM; HUMAN; HUMAN EXPERIMENT; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0033563742     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00112-4     Document Type: Article

References (45)

1. Thomasset M. Vitamin D and the immune system. Pathol Biol (Paris). 42:1994;163-172.
2. Bhalla A.K., Amento E.P., Serog B., Glimcher L.H. 1,25-Dihydroxyvitamin D inhibits antigen-induced T cell activation. J Immunol. 133:1984;1748-1754.
3. 3. J Clin Invest. 79:1987;1659-1664.
4. 3. J Steroid Biochem Mol Biol. 53:1995;599-602.
5. Trembleau S., Germann T., Gately M.K., Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today. 16:1995;383-386.
6. 3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab. 57:1983;1308-1311.
7. 3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab. 68:1989;7747-7777.
8. 3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 15:1995;5789-5799.
9. 3. Involvement of NF-kB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 101:1998;252-262.
10. 3 attenuates the expression of experimental murine lupus of MRL/I mice. Autoimmunity. 12:1992;143-148.
11. 3 prevents insulitis in NOD mice. Diabetes. 41:1992;1491-1495.
12. 3 suppresses the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 87:1991;1103-1107.
13. 3. J Neuroimmunol. 61:1995;151-160.
14. 3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA. 93:1996;7861-7864.
15. Librau R.S., Singer S.M., McDevitt H.O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 16:1995;34-48.
16. Hillert J. Human leukocyte antigen studies in multiple sclerosis. Ann Neurol. 36:1994;S15-S17.
17. Compston D.A.S., Kellar Wood H., Robertson N., Sawcer S., Wood N.W. Genes and susceptibility to multiple sclerosis. Acta Neurol Scand. 161:(Suppl):1995;43-51.
18. Ebers G.C., Kukay K., Bulmann D.E., et al. A full genome search in multiple sclerosis. Nat Genet. 13:1996;472-476.
19. Haines J.L., Ter-Minassian M., Bazyk A., et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nat Genet. 13:1996;469-471.
20. Sawcer S., Jones H.B., Feakes R., et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosomes 6p21 and 17q22. Nat Genet. 13:1996;464-468.
21. Fukazawa T., Hamada T., Tashiro K., Moriwaka F., Yanagihara T. Acute transverse myelopathy in multiple sclerosis. J Neurol Sci. 100:1990;217-222.
22. Fukazawa T., Miyasaka K., Tashiro K., et al. MRI findings of multiple sclerosis with acute transverse myelopathy. J Neurol Sci. 110:1992;27-31.
23. Fukazawa T., Hamada T., Moriwaka F., Tashiro K. Acute transverse myelopathy in MS: Clinical considerations. Intern MS J. 1:1994;26-33.
24. Fukazawa T., Hamada T., Tashiro K., et al. HLA profiles of multiple sclerosis in Hokkaido, the northernmost island of Japan. Acta Neurol Scand. 86:1992;517-520.
25. Kira J., Kanai T., Nishimuta Y., et al. Western versus Asian types of multiple sclerosis: Immunogenetically and clinically distinct disorders. Ann Neurol. 40:1996;569-574.
26. Ito H., Yamasaki K., Kawano Y., et al. HLA-DP-associated susceptibility to the optico-spinal form of multiple sclerosis in the Japanese. Tissue Antigen. 52:1998;179-182.
27. Fukazawa T., Kikuchi S., Sasaki H., et al. Anti-nuclear antibodies and the optic spinal form of multiple sclerosis. J Neurol. 244:1997;483-488.
28. Fukazawa T., Moriwaka F., Mukai M., Hamada T., Koike T., Tashiro K. Anticardiolipin antibodies in Japanese patients with multiple sclerosis. Acta Neurol Scand. 88:1993;184-189.
29. Fukazawa T., Hamada T., Kikuchi S., Sasaki H., Tashiro K. Antineutrophil cytoplasmic antibodies and the optic-spinal cord of multiple sclerosis in Japan. J Neurol Neurosurg Psychiatry. 61:1996;203-204.
30. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 13:1983;227-231.
31. Fukazawa T., Tashiro K., Hamada T., et al. Multiple sclerosis in Hokkaido, the northernmost island of Japan: Prospective analyses of clinical features. Intern Med. 31:1992;349-352.
32. Morrison N.A., Qi J.C., Tokita A., et al. Prediction of bone density from vitamin D receptor alleles. Nature. 367:1994;284-287.
33. Fukazawa T., Kikuchi S., Sasaki H., Hamada K., Hamada T., Miyasaka K., Tashiro K. The significance of oligoclonal bands in multiple sclerosis in Japan: Relevance of immunogenetic background. J Neurol Sci. 158:1998;209-214.
34. Mangelsdolf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell. 83:1995;841-850.
35. Brachet P., Garcion E., Nataf S., Naveilhan P., Neveu I., Darcy F., Wion D. Vitamin D, an hormone involved in the control of brain homeostasis. Norman A.W., Bouillon R., Thomasset M., Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone. 1997;593-599 University of California, Riverside.
36. Schwartz G.G. Hypothesis: Calcitriol mediates pregnancy's protective effect on multiple sclerosis. Arch Neurol. 50:1993;455.
37. McMorris F.A., McKinnon R.D. Regulation of oligodendrocyte development and CNS myelonation by growth factors: Prospects for therapy of demyelinating disease. Brain Pathol. 6:1996;313-329.
38. Xiao B.-G., Link H. Immune regulation within the central nervous system. J Neurol Sci. 157:1998;1-12.
39. Schwartz G.G. Multiple sclerosis and prostate cancer: what do their similar geographies suggest? Neuroepidemiology. 11:1992;244-254.
40. Acheson E.D., Bachrach C.A., Wright F.M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psyciat (Scand). 35:(Suppl 147):1960;132-147.
41. Nieves J., Cosman F., Herbert J., Shen V., Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology. 44:1994;1687-1692.
42. Cosman F., Nieves J., Komer L., et al. Fracture history and bone loss in patients with MS. Neurology. 51:1998;1161-1165.
43. Qu Z., Dayal A., Jenson M., Arnason B. All-trans retinoic acid potentiates the ability of interferon beta-1b to augument suppressor cell function in multiple sclerosis. Arch Neurol. 55:1998;315-321.
44. Weber F., Polak T., Gunther A., et al. Synergic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol. 44:1998;27-34.
45. Matsuyama T., Ishii S., Tokita A., et al. Vitamin D receptor genotypes and bone mineral density. Lancet. 345:1995;1238-1239.